13 results
8-K
EX-99.2
TXMD
TherapeuticsMD Inc
5 Dec 22
TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma
7:31am
difficulties in employee retention as a result of the proposed transaction; (6) risks related to diverting management’s attention from ongoing business
8-K
EX-99.1
TXMD
TherapeuticsMD Inc
5 Dec 22
TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma
7:31am
plans and operations and potential difficulties in employee retention as a result of the proposed transaction; (6) risks related to diverting
SC 14D9/A
EX-99
TXMD
TherapeuticsMD Inc
13 Jul 22
Tender offer solicitation (amended)
7:53am
and operations and potential difficulties in employee retention as a result of the failure of the proposed transaction; risks related to diverting management’s
SC TO-T/A
EX-99
Athene Merger Sub, Inc.
23 Jun 22
Third party tender offer statement (amended)
4:07pm
disrupts current plans and operations and potential difficulties in employee retention as a result of the proposed transaction; (6) risks related
SC TO-T
EX-99
Athene Merger Sub, Inc.
6 Jun 22
Third party tender offer statement
5:02pm
generally; (5) risks that the proposed transaction disrupts current plans and operations and potential difficulties in employee retention as a result
SC TO-C
tob33v95uh7 c1
31 May 22
Information about tender offer
10:02am
SC TO-C
EX-99.1
pp2xtyffsz0
31 May 22
Information about tender offer
10:02am
SC14D9C
EX-99.1
mdje01f669v 5o0j
31 May 22
Written communication relating to third party tender offer
7:55am
SC14D9C
9xmq9e
31 May 22
Written communication relating to third party tender offer
7:55am
8-K
2s8exr2
31 May 22
TherapeuticsMD and EW Healthcare Partners
6:47am
8-K
EX-99.1
cn4xzegxkznhd t9
31 May 22
TherapeuticsMD and EW Healthcare Partners
6:47am
- Prev
- 1
- Next